21st Century Business Herald reporter Ji Yuanyuan Shanghai Report October 29, 2021 is world psoriasis day (wpd), and today is also the eighteenth world psoriasis day.
Recently, at the "Standing in the Light - World Psoriasis Day" public welfare activity sponsored by the Dermatological and Venereal Diseases Professional Committee of the Chinese Association of Integrative Traditional and Western Medicine, the "2021 China Psoriasis Patient Happiness Survey" was released. Professor Gu Jun, chairman of the Dermatological and Venereal Diseases Professional Committee of the Chinese Association of Integrative Traditional and Western Medicine, interpreted the results of the survey on the happiness, quality of life, and satisfaction of diagnosis and treatment of patients with psoriasis.
Professor Gu Jun introduced that psoriasis brings serious psychological burdens to patients, including insomnia, feeling nervous and stressed, lonely, lack of friendship, feeling that they are not social and women's stress levels are significantly higher than men, and their emotional depression is mainly related to the pain caused by the disease, lack of confidence in the current treatment and other factors.
According to epidemiological surveys, the number of psoriasis in China has reached 6.5 million, but only 20% of patients choose to go to the hospital. According to the "2021 China Psoriasis Patient Happiness Survey", more than 80% of patients are aged between 18-50 years old.
The disease may have a certain impact on the employment of patients and the life of the patient. This also makes it extremely important to strengthen society's awareness of psoriasis as the number of patients continues to increase.
Known as "God's tattoo", psoriasis is a chronic, recurrent, inflammatory, systemic disease of environmentally induced stimulation, multigenic genetic control, immune-mediated, commonly known as "psoriasis", typically manifested as scaly erythema or plaque, limited to one place or widely distributed throughout the body. Most patients worsen or relapse in the winter and resolve in the summer. However, this "ringworm" is not a "ringworm", this psoriasis is not a "ringworm" caused by a fungal infection of the skin.
Although psoriasis is not contagious, due to skin desquamation and erythema symptoms, many psoriasis patients are prone to discrimination and prejudice, and they are suffering from pain and suffering while carrying overloaded social and psychological pressure. Moreover, many psoriasis patients mistakenly believe in home remedies, resulting in repeated attacks and even worsening of the condition.
Professor Gu Jun introduced that according to the "2021 China Psoriasis Patient Happiness Survey" report, 332 patients with psoriasis were investigated, and more than 80% of the patients were aged between 18-50 years old, and the proportion of mild to moderate psoriasis patients was 68%. At the same time, the report shows that skin problems have an impact on the daily mood of more than 96% of patients. Among them, the main reasons affecting emotions are pain caused by diseases, itching and lack of confidence in future treatment, etc. In the past month, nearly 76% of psoriasis patients have been affected by sleep, and more than 66% of patients have brought serious psychological burdens such as feeling unaccompanied, lack of friendship and unsociable, and the proportion of women is higher than that of men.
At the same time, nearly 80% of patients have never received psychological or spiritual treatment help, which also makes the life treatment of psoriasis patients also seriously affected by the disease, including career choices, spending time with the same time, etc., and the impact of men is greater than that of women. But women are generally more affected than men when it comes to spending time with family or friends and residual expectations.
"In the treatment process of psoriasis patients, efficacy and treatment costs are the two most critical factors affecting patients' adherence to treatment, of which only 33% of patients can receive annual treatment costs greater than 10,000 yuan." More than half of the patients are not satisfied with the treatment status quo, the treatment effect is not good, the application time is too long, and the high cost of treatment is not satisfied with the three main factors, which also makes only 10% of patients will follow the doctor's requirements regularly. Professor Gu Jun pointed out to the 21st Century Business Herald and other media that all psoriasis patients should strictly follow the medical instructions on time, in quantity and according to the course of treatment under the guidance of professional doctors in regular hospitals. At this stage, although psoriasis cannot be cured, it helps to maintain no recurrence and achieve clinical cure after adhering to the doctor's instructions. At the same time, it also calls on the public to give more understanding and care to psoriasis patients.
Judging from the current status of patient diagnosis and treatment, the psychological burden of psoriasis patients is due to the lack of cognition. From the small advertisements posted on the telephone pole to cure "psoriasis", the elders in the family are still superstitious and unreliable home remedies, and the fear of being infected and avoiding patients, we can see how deep people misunderstand psoriasis. More patients mistake psoriasis for skin cancer, which seriously affects their own mentality after the disease, so that they fall into the wrong area and delay treatment.
In addition, on many public platforms, patients have written their own medical experience: after the diagnosis of psoriasis in the hospital, the family felt that the treatment of such diseases needed to use folk remedies, and after listening to the advice of the family, choosing to use the cow's placenta to bake dry and grind into a powder and stir in edible sesame oil to replace the use of drugs, the result became more and more serious.
In fact, the World Health Organization (WHO) as early as 2016 released the "Global Report on Psoriasis" pointed out that 93% of patients expect complete clearance of skin lesions, 94% expect rapid improvement of skin lesions, and 83% expect stable and unbroken conditions. However, according to the actual situation, the classification of psoriasis can be clinically divided into common type, pustular type, erythroderma type, arthropathy and other types. Among them, most of the patients with psoriasis in China are mainly psoriasis vulgaris, and the proportion of patients with moderate and severe psoriasis is high, accounting for about 20%, and most patients have a course of more than 10 years.
According to the severity of the disease, psoriasis can be divided into three grades: light, moderate and severe. Professor Zhang Xuejun, director of the Institute of Dermatology of Fudan University (Affiliated Huashan Hospital), said in an interview with the 21st Century Business Herald: "The area of each of our palms is 1% of the surface area of our human body. When the rash on your body does not exceed 3 palm areas, it is mild; when it reaches 3-10, even if it is moderate, more than 10 is severe. "But the pathogenesis of psoriasis is still unclear. It is generally believed that the incidence of psoriasis is related to multiple factors such as genetics, immunity, and environment, and some patients have a family history of psoriasis.
"In addition, bad emotions such as nervousness and anxiety can also induce or aggravate psoriasis, inflammatory cell infiltration and inflammatory factors have an important link with their onset, and people who have been in or live in humid environments for a long time are relatively more likely to have psoriasis... These groups are all at high risk of psoriasis, and it is particularly necessary to strengthen the diagnosis of the disease and achieve early diagnosis and treatment. Professor Gu Jun added.
According to public information, there are three main forms of treatment for psoriasis: local treatment, light therapy, and systemic treatment. The choice of treatment is based on the severity of psoriasis. Mild psoriasis is usually treated topically, with light therapy if it is not effective. Moderate to severe psoriasis requires systemic treatment. Among them, psoriasis has external drug treatment, internal drug treatment, biological drug preparations, traditional Chinese medicine and other therapies.
Prior to 2003, treatment of psoriasis relied mainly on non-biological agents such as topical corticosteroids, vitamin D analogues, keratin strippers, and calcineurin inhibitors, while for more severe diseases, treatment was mainly methotrexate or cyclosporine. With the advent of a range of target-specific biologics, such as tumor necrosis factor (tnf) inhibitors and interleukin (IL) inhibitors, the efficacy of psoriasis treatments has improved significantly, driving the rapid growth of the psoriasis drug market.
According to the iqvia database, the global psoriasis drug market in 2020 increased by 192% compared with 2015, and the global psoriasis drug market reached $25.3 billion, ranking first in the field of dermatology treatment, and is expected to continue to maintain this top position in the next decade.
In China, the psoriasis drug market also has good prospects. According to the data of the intranet, in recent years, the psoriatic drug market in public hospitals in key provinces and cities has exceeded 100 million yuan, and sales in the first half of this year are close to 60 million yuan, an increase of 19.39% year-on-year. In the first half of 2021, the sales of psoriasis monoclonal antibody drugs in key provincial and municipal public hospitals increased by more than 10 times year-on-year. Among them, Novartis' siguchiyuzumab (Keshan Ting) is in the first place, entering the national medical insurance directory to drive the market volume, occupying more than 90% of the share, Xi'an Jansen's ussnuzumab (Starano) although it was approved earlier than Ke Shan Ting, but because there is no price reduction into the national medical insurance directory, it only accounts for 2.76% of the share. In addition, Eli Lilly's echizumab (Tuosimir), Janssen's Guseziyu monoclonal antibody (Tenoya) and Concord Fermented Unicorn's broliyuzumab (Limef) also have a lower share.
In this regard, a chief analyst of the pharmaceutical industry told the 21st Century Economic Herald reporter that the rising prevalence rate will continue to drive the positive growth of the psoriasis drug market, but its growth rate will gradually slow down, and in the future, the psoriasis drug market will continue to occupy the leading position in the global skin disease treatment market. In addition, in the domestic market, under the general trend of entering the national medical insurance directory and the active price reduction of foreign varieties to compete for the market, the proportion of more innovative drugs to treat psoriasis will continue to increase, and the Chinese market will be further expanded, and the psoriasis drug market will usher in a broad blue ocean.
For more information, please download the 21 Finance app